DK2688907T3 - Dominant negativ hsp110 mutant og dens anvendelse til prognose og behandling af cancere - Google Patents

Dominant negativ hsp110 mutant og dens anvendelse til prognose og behandling af cancere Download PDF

Info

Publication number
DK2688907T3
DK2688907T3 DK12710730.8T DK12710730T DK2688907T3 DK 2688907 T3 DK2688907 T3 DK 2688907T3 DK 12710730 T DK12710730 T DK 12710730T DK 2688907 T3 DK2688907 T3 DK 2688907T3
Authority
DK
Denmark
Prior art keywords
hsp110
cancer
msi
mutated
patient
Prior art date
Application number
DK12710730.8T
Other languages
English (en)
Inventor
Carmen Garrido
Alex Duval
Original Assignee
Inst Nat De La Sante Et De La Rech Medicale (Inserm)
Université de Bourgogne
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat De La Sante Et De La Rech Medicale (Inserm), Université de Bourgogne filed Critical Inst Nat De La Sante Et De La Rech Medicale (Inserm)
Application granted granted Critical
Publication of DK2688907T3 publication Critical patent/DK2688907T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Claims (12)

1. Muteret varmechok-protein 110 (HSP110) der består af en aminosyresekvens af SEQ ID NO: 1.
2. Isoleret nukleinsyre omfattende en sekvens der koder for det muterede HSPllO-protein ifølge krav 1.
3. Anvendelse af et muteret HSP110 ifølge krav 1, en nukleinsyre ifølge krav 2, og/eller af en mikrosatellit-gentagelse af 17 thymidin nukleotider lokaliseret i splejsnings-acceptorsitet af intron 8 i genet der koder for HSP110 som en biomarkør til prognose for overlevelse og/eller responset til en behandling af en patient der er ramt af en cancer.
4. In vitro-fremgangsmåde til prognose for overlevelse og/eller respons til en behandling af en patient der er ramt af cancer, hvilken fremgangsmåde omfatter trinnene at: a) måle ekspressionen af et muteret HSP110 ifølge krav 1 i en biologisk prøve fra patienten; og/eller b) bestemme længden af thymidin-gentagelser afen mikrosatellitgentagelse af 17 thymidin nukleotider lokaliseret i splejsnings-acceptorsitet af intron 8 i genet der koder for HSP110; c) og korrelere ekspressionsniveauet målt ved trin a) og/eller længden af thymidin-deletionen identificeret ved trin b) med prognosen for patienten, og derved bestemme prognosen for patienten.
5. In vitro-fremgangsmåden ifølge krav 4, hvor fremgangsmåden omfatter trinnene at: a) bestemme længden af thymidin-deletionen afen mikrosatellitgentagelse af 17 thymidin nukleotider lokaliseret i splejsnings-acceptorsitet af intron 8 i genet der koder for HSP110; b) og korrelere længden af thymidin-gentagelsen identificeret ved trin a) med prognosen for patienten, og derved bestemme prognosen for patienten, hvor en deletion på mindst 5 thymidiner indenfor gentagelsen er indikation for en god prognose for overlevelse og/eller respons på behandlingen.
6. In vitro-fremgangsmåden ifølge krav 4, hvor fremgangsmåden omfatter trinnene at: a) måle ekspressionen af et muteret HSP110 ifølge krav 1 i en biologisk prøve fra patienten; b) måle ekspressionen af et muteret HSP110 ifølge krav 1 i en negativ kontrolprøve; hvor en signifikant højere ekspression af muteret HSP målt ved trin a) i sammenligning med ekspressionen målt ved trin b) er indikation for en god prognose for overlevelse og/eller respons på behandlingen.
7. In vitro-fremgangsmåden ifølge krav 4, hvor fremgangsmåden omfatter trinnene at: a) måle ekspressionen af et muteret HSP110 ifølge krav 1 i en biologisk prøve fra patienten; b) måle ekspressionen af vildtype HSP110 i den biologiske prøve; c) sammenligne ekspressionen målt ved trin a) og b), og derved bestemme prognosen for patienten.
8. In vitro-fremgangsmåde til diagnosticering af MSI-fænotypen afen cancer, hvilken fremgangsmåde omfatter trinnene at: a) genotype-bestemme eller sekventere mikrosatellit-gentagelsen af 17 thymidin nukleotider lokaliseret i splejsnings-acceptorsitet af intron 8 i genet der koder for HSP110 i en biologisk prøve fra en patient der sandsynligvis er påvirket af en cancer med MSI-fænotype; b) detektere tilstedeværelsen eller fraværet af ustabilitet af mikrosatellitgentagelsen, hvor detektionen af ustabilitet af mikrosatellit-gentagelsen i den biologiske prøve fra patienten indikerer at patienten lider af en cancer med MSI-fænotype.
9. In vitro-fremgangsmåde til bestemmelse af en terapeutisk behandling der er egnet til behandling af et individ der lider af cancer der sandsynligvis har en MSI-fænotype, hvor fremgangsmåden omfatter trinnene at: a) bestemme længden af thymidin-gentagelser afen mikrosatellitgentagelse af 17 thymidin nukleotider lokaliseret i splejsnings-acceptorsitet af intron 8 i genet der koder for varmechok-protein 110 (HSP110) i en biologisk prøve fra patienten, og b) bestemme en passende terapeutisk behandling for individet baseret på længden af thymidin-gentagelsen.
10. Fremgangsmåden ifølge et hvilket som helst af kravene 4 til 9, hvor canceren er valgt fra gruppen bestående af colorektal cancer, mavecancer, endometriecancer, blærecancer, urinvejscancer, ovariecancer, prostatacancer, lymphomer, leukæmier, glioblastom, astrocytom og neuroblastom.
11. Fremgangsmåden ifølge krav 10, hvor canceren er colorektal cancer.
12. Kit omfattende eller bestående af: - middel til specifikt at detektere tilstedeværelsen af muteret HSP110 ifølge krav 1, og/eller - middel til specifikt at detektere længden af en mikrosatellit-gentagelse af 17 thymidin nukleotider lokaliseret i splejsnings-acceptorsitet af intron 8 i genet der koder for HSP110.
DK12710730.8T 2011-03-24 2012-03-26 Dominant negativ hsp110 mutant og dens anvendelse til prognose og behandling af cancere DK2688907T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11305330 2011-03-24
PCT/EP2012/055339 WO2012127062A1 (en) 2011-03-24 2012-03-26 Dominant negative hsp110 mutant and its use in prognosing and treating cancers

Publications (1)

Publication Number Publication Date
DK2688907T3 true DK2688907T3 (da) 2016-06-13

Family

ID=44453822

Family Applications (1)

Application Number Title Priority Date Filing Date
DK12710730.8T DK2688907T3 (da) 2011-03-24 2012-03-26 Dominant negativ hsp110 mutant og dens anvendelse til prognose og behandling af cancere

Country Status (10)

Country Link
US (2) US20140038900A1 (da)
EP (1) EP2688907B1 (da)
JP (1) JP6045563B2 (da)
CN (1) CN103562218B (da)
AU (1) AU2012230259B2 (da)
CA (1) CA2830787C (da)
DK (1) DK2688907T3 (da)
ES (1) ES2575980T3 (da)
IL (1) IL228552B (da)
WO (1) WO2012127062A1 (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105431549A (zh) * 2013-03-27 2016-03-23 麦克·明照·邢 癌症中的tert(端粒酶逆转录酶)基因启动子突变
WO2014154898A1 (en) 2013-03-29 2014-10-02 Institut National De La Sante Et De La Recherche Medicale (Inserm) Prognosis and treatment of cancers
JP6260986B2 (ja) * 2013-10-26 2018-01-17 国立大学法人名古屋大学 フィラグリン遺伝子変異検出法及びその用途
CN107641649B (zh) * 2016-07-22 2021-03-19 中山大学附属第六医院 检测微卫星nr27位点稳定性的引物对、试剂盒及方法
WO2018152095A1 (en) * 2017-02-14 2018-08-23 Celgene Corporation Treatment of cancer with smg1-inhibitors
DK3652606T3 (da) * 2017-07-12 2023-03-13 Nouscom Ag Universel vaccine baseret på delte tumorneoantigener til forebyggelse og behandling af cancere med mikrosatellitinstabilitet (msi)
CN109593847B (zh) * 2017-09-29 2023-04-11 中山大学附属第六医院 检测微卫星nr24位点稳定性的引物对、试剂盒及方法
CN110770838B (zh) * 2017-12-01 2023-12-19 Illumina公司 用于确定体细胞突变克隆性的方法和系统
US20210186941A1 (en) 2018-08-06 2021-06-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Compounds targeting hsp110 protein for cancer treatment
CN111850129B (zh) * 2020-08-17 2022-09-30 中山大学附属第六医院 检测微卫星nr21位点稳定性的引物对、试剂盒及方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE548354T1 (de) * 2002-07-24 2012-03-15 Ptc Therapeutics Inc Ureido-substituierte benzoesäureverbindungen und ihre verwendung für die nonsense-suppression und behandlung von erkrankungen
DE602006010522D1 (de) * 2005-08-12 2009-12-31 Astellas Pharma Inc Verfahren zur identifizierung des zielproteins eines wirkstoffs und verfahren zum screening eines therapeutischen wirkstoffs gegen diabetes mittels des zielproteins
FR2912745A1 (fr) * 2007-02-19 2008-08-22 Centre Nat Rech Scient Nouveaux composes derives d'indole et compositions pharmaceutiques les contenant
CN101670115B (zh) * 2009-07-31 2011-07-27 中国人民解放军第三军医大学 乙酰肝素酶与热休克蛋白的复合物及其制备方法和应用
WO2014154898A1 (en) * 2013-03-29 2014-10-02 Institut National De La Sante Et De La Recherche Medicale (Inserm) Prognosis and treatment of cancers

Also Published As

Publication number Publication date
CN103562218A (zh) 2014-02-05
JP6045563B2 (ja) 2016-12-14
CN103562218B (zh) 2015-09-09
JP2014512174A (ja) 2014-05-22
US10175244B2 (en) 2019-01-08
CA2830787C (en) 2019-11-12
AU2012230259B2 (en) 2017-04-06
IL228552A0 (en) 2013-12-31
US20150377892A1 (en) 2015-12-31
IL228552B (en) 2019-02-28
AU2012230259A1 (en) 2013-10-10
US20140038900A1 (en) 2014-02-06
ES2575980T3 (es) 2016-07-04
WO2012127062A1 (en) 2012-09-27
CA2830787A1 (en) 2012-09-27
EP2688907A1 (en) 2014-01-29
EP2688907B1 (en) 2016-04-27

Similar Documents

Publication Publication Date Title
DK2688907T3 (da) Dominant negativ hsp110 mutant og dens anvendelse til prognose og behandling af cancere
EP2456889B1 (en) Markers for endometrial cancer
JP6223822B2 (ja) 未分化リンパ腫キナーゼ（ａｌｋ）キナーゼ阻害剤に耐性である癌の診断および治療のための方法および組成物
Iyama et al. Identification of three novel fusion oncogenes, SQSTM1/NTRK3, AFAP1L2/RET, and PPFIBP2/RET, in thyroid cancers of young patients in Fukushima
KR20140093991A (ko) 인간 notch 수용체 돌연변이 및 그의 용도
CA2631630A1 (en) Fc.gamma. polymorphisms for predicting disease and treatment outcome
EP3334842B1 (en) Methods of treating ophthalmic disorders
WO2006078911A2 (en) Gitr antibodies for the diagnosis of nsclc
EP4103752A2 (en) Methods and compositions for identifying castration resistant neuroendocrine prostate cancer
WO2004044164A2 (en) Method for identifying risk of melanoma and treatments thereof
US20170233818A1 (en) Multiple target nucleic acid detection method using clamping probe and detection probe
WO2014154898A1 (en) Prognosis and treatment of cancers
US20050064442A1 (en) Methods for identifying risk of breast cancer and treatments thereof
US20100028867A1 (en) LRRTM1 Compositions and Methods of Their Use for the Diagnosis and Treatment of Cancer
US20050118606A1 (en) Methods for identifying risk of breast cancer and treatments thereof
NUNES Method for diagnosing myeloproliferative chronic myelomonocytic leukemia or unclassified myeloproliferative myelodysplastic neoplasm
WO2016042137A1 (en) Method for diagnosing myeloproliferative chronic myelomonocytic leukemia or unclassified myeloproliferative myelodysplastic neoplasm